핵의학 장비 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the nuclear medicine equipment market size is projected to be USD 6.70 billion in 2025, USD 6.97 billion in 2026, and reach USD 8.39 billion by 2031, growing at a CAGR of 3.80% from 2026 to 2031.

This report is Segmented by Product Type (SPECT Systems, Hybrid SPECT/CT, PET Systems, and More), Detector Technology (NaI Cameras, CZT Digital SPECT, and More), Application (Oncology, Cardiology, Neurology, and More), End User (Hospitals, Imaging Centers, Academic Institutes, and More), and Geography (North America, Europe, Asia Pacific, and More). Market Forecasts in Value (USD).

Global Nuclear Medicine Equipment Market Trends and Insights

Rising Burden of Oncology & Cardiology Cases

Cancer incidence is projected to climb 47% by 2050, pushing clinicians toward molecular techniques that can track tiny treatment responses undetectable on CT or MR. The 2024 FDA nod for flurpiridaz F-18 now lets care teams perform stress PET studies with higher accuracy and lower isotope decay risk, expanding nuclear cardiology reach. Because aging populations drive both cancer and coronary disease, hospitals upgrade tracer inventories and schedule additional imaging slots to keep pace with combined oncology and cardiology demand. PET-based perfusion studies, though costlier than SPECT, gain favor as evidence mounts for better outcomes in complex coronary artery disease. Consequently, long-term procedure volume growth remains resilient regardless of short-term macroeconomic swings, reinforcing the nuclear medicine equipment market as an essential service.

Rapid Adoption of Hybrid PET/CT & SPECT/CT Scanners

Hybrid scanners fuse metabolic and anatomical data in one acquisition, eliminating registration errors and halving patient throughput time. The Biograph Trinion PET/CT, cleared in 2024, illustrates this shift with air-cooled detectors that cut power use by 46% while delivering 239-ps time-of-flight performance. Health systems view these gains as strategic because faster scans increase daily capacity without expanding staff, a critical benefit in tight labor markets. Hybrid systems also simplify reporting by synchronizing voxel-level anatomical landmarks with tracer uptake, improving diagnostic confidence in oncology staging and therapy monitoring. Long axial FOV designs, such as the uEXPLORER, cover the entire body in under 60 seconds and reduce radiopharmaceutical dose by more than 80%. These operational and clinical advantages position hybrid platforms as the growth engine of the nuclear medicine equipment market.

High Capital & Service Contracts for Scanners

A state-of-the-art PET/CT can cost USD 2-4 million, and annual service fees often reach 10% of the purchase price, straining the budgets of smaller hospitals. Required shielding, HVAC upgrades, and IT interfaces double project outlays, making return-on-investment calculations difficult. Financing models are evolving; Positron's rental plan for the NeuSight PET-CT reduces upfront cash yet still locks providers into long service terms. Complex software stacks require vendor engineers for routine updates, and downtime penalties cut into margins. These realities slow penetration in mid-income nations, tempering overall growth in the nuclear medicine equipment market.

Other drivers and restraints analyzed in the detailed report include:

1. Reimbursement Expansion for Molecular Imaging in OECD
2. Long-Axial FOV PET/CT Enabling Ultra-Low-Dose Workflows
3. Supply-Chain Fragility of Short-Lived Radio-Isotopes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

SPECT scanners accounted for 52.3% of revenue in 2024, as they remain affordable and reliable for routine cardiac and bone studies. Hybrid PET/CT systems, on the other hand, are expected to expand at a 7.9% CAGR as clinicians prioritize precision diagnostics. The nuclear medicine equipment market benefits from hybrid devices, which elevate clinical confidence while optimizing workflow. Advances such as AI-assisted protocol selection and iterative reconstruction increase sensitivity while reducing doses, thereby reinforcing demand. In a parallel trend, planar cameras remain steady for thyroid and sentinel-node imaging, although their share declines as 3-D modalities proliferate.

Across the forecast, vendors embed digital detectors and cloud-enabled analytics into all scanner classes. GE HealthCare's launch of the flurpiridaz-compatible PET protocol in 2025 prompts mid-tier hospitals to add PET suites, boosting the nuclear medicine equipment market size for high-resolution cardiac imaging. Long-axial-FOV PET/CT systems extend use cases to dynamic tracer studies and whole-body dosimetry, capturing new research budgets and increasing revenue diversity.

NaI Anger cameras delivered 68.1% of 2024 shipments, reflecting decades of a large installed base and a low unit price. Yet CZT technology is advancing at a 12.8% CAGR and increasingly captures replacement cycles. Providers adopt CZT because higher energy resolution distinguishes overlapping isotopes in dual-isotope protocols, enhancing cardiac diagnostics. SiPM-based PET detectors also see rising orders for their picosecond timing, which sharpens image quality. Analog PMT configurations remain prevalent in cost-sensitive settings, helping to sustain baseline volume in the nuclear medicine equipment market.

Clinical trials underline CZT superiority, especially in coronary perfusion, where count sensitivity directly informs treatment plans. Declining semiconductor costs and multi-vendor competition compress prices, widening access. Ongoing R&D into CdTe and HgI2 substrates suggests further improvements in resolution. Integration with AI-powered denoising software means future systems deliver higher clarity at lower administered doses, solidifying the digital transition within the nuclear medicine equipment market.

Complete Report Scope:

• By Product Type
  • SPECT Systems
  • Hybrid SPECT/CT Systems
  • PET Systems
  • Hybrid PET/CT Systems
  • Planar Scintigraphy Cameras
• By Detector Technology
  • NaI Scintillation (Anger) Cameras
  • CZT Digital SPECT Cameras
  • SiPM-Based PET Detectors
  • Analog PMT PET Detectors
  • Others (CdTe, HgI?)
• By Application
  • Oncology
  • Cardiology
  • Neurology
  • Orthopedics & Musculoskeletal
  • Other Clinical Areas
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes
  • Specialty Clinics
  • Mobile Imaging Service Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 34.7% of 2024 revenue following the implementation of CMS reimbursement reform and ongoing research funding, which accelerated equipment renewals. Providers in the United States quickly integrate AI tools to streamline protocol selection, while Canadian hospitals invest in cyclotrons to achieve self-reliance in isotope production. Mexico upgrades imaging fleets in metropolitan areas to attract medical tourists, adding incremental volumes.

Europe ranks second in market size, anchored by Germany's university-hospital network and the Netherlands' isotope reactors. However, the 2024 Mo-99 shortage exposed reliance on single reactors and spurred EU grants for diversified production. The United Kingdom's NHS embeds molecular imaging pathways in national cancer plans, stabilizing procedure volumes even during fiscal tightening. Central and Eastern European nations are experiencing double-digit growth as they modernize their diagnostic infrastructure, thereby generating new demand for nuclear medicine equipment.

The Asia Pacific is the fastest-growing region, with a 7.2% CAGR, driven by rising chronic disease incidence and government capacity-building programs. China operates more than 1,200 nuclear medicine sites serving millions of patients each year. Japan's mature ecosystem now benefits from GE HealthCare's acquisition of Nihon Medi-Physics, which secures domestic tracer supply. India scales PET-CT capacity in tier-two cities, and Australia backs theranostic trials targeting rare cancers. These initiatives compound into robust regional momentum for the nuclear medicine equipment market.

1. GE Healthcare
2. Siemens Healthineers
3. Koninklijke Philips
4. Canon
5. United Imaging Healthcare
6. Spectrum Dynamics Medical
7. Digirad
8. Mediso
9. Neusoft Medical Systems
10. DDD-Diagnostics
11. Positron
12. Oncovision
13. CMR Naviscan
14. SurgicEye
15. Curium Cameras (Sentinella)
16. Shimadzu
17. FUJIFILM
18. Cubresa Inc.
19. Bruker BioSpin
20. Molecular Devices

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden Of Oncology & Cardiology Cases
  • 4.2.2 Rapid Adoption Of Hybrid PET/CT & SPECT/CT Scanners
  • 4.2.3 Reimbursement Expansion For Molecular Imaging In OECD
  • 4.2.4 Government Isotope-Production Investments (E.G., Mo-99)
  • 4.2.5 Commercial Rollout Of CZT Digital SPECT Cameras
  • 4.2.6 Long-Axial FOV PET/CT Enabling Ultra-Low-Dose Workflows
• 4.3 Market Restraints
  • 4.3.1 High Capital & Service Contracts For Scanners
  • 4.3.2 Supply-Chain Fragility Of Short-Lived Radio-Isotopes
  • 4.3.3 Tightening Radioactive-Waste Disposal Regulations
  • 4.3.4 Shortage Of Certified Nuclear-Medicine Technologists
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Product Type
  • 5.1.1 SPECT Systems
  • 5.1.2 Hybrid SPECT/CT Systems
  • 5.1.3 PET Systems
  • 5.1.4 Hybrid PET/CT Systems
  • 5.1.5 Planar Scintigraphy Cameras
• 5.2 By Detector Technology
  • 5.2.1 NaI Scintillation (Anger) Cameras
  • 5.2.2 CZT Digital SPECT Cameras
  • 5.2.3 SiPM-Based PET Detectors
  • 5.2.4 Analog PMT PET Detectors
  • 5.2.5 Others (CdTe, HgI?)
• 5.3 By Application
  • 5.3.1 Oncology
  • 5.3.2 Cardiology
  • 5.3.3 Neurology
  • 5.3.4 Orthopedics & Musculoskeletal
  • 5.3.5 Other Clinical Areas
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Academic & Research Institutes
  • 5.4.4 Specialty Clinics
  • 5.4.5 Mobile Imaging Service Providers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Russia
    • 5.5.2.7 Rest of Europe
  • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 GE HealthCare
  • 6.3.2 Siemens Healthineers
  • 6.3.3 Philips Healthcare
  • 6.3.4 Canon Medical Systems
  • 6.3.5 United Imaging Healthcare
  • 6.3.6 Spectrum Dynamics Medical
  • 6.3.7 Digirad Corporation
  • 6.3.8 Mediso Ltd.
  • 6.3.9 Neusoft Medical Systems
  • 6.3.10 DDD-Diagnostics
  • 6.3.11 Positron Corporation
  • 6.3.12 Oncovision
  • 6.3.13 CMR Naviscan
  • 6.3.14 SurgicEye
  • 6.3.15 Curium Cameras (Sentinella)
  • 6.3.16 Shimadzu Medical
  • 6.3.17 Fujifilm Healthcare
  • 6.3.18 Cubresa Inc.
  • 6.3.19 Bruker BioSpin
  • 6.3.20 Molecular Devices LLC

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment